What service do you need? Contact Request

NCT05570253

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

← Hub

Registry fields

Overall status: RECRUITING
Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer
Study type: INTERVENTIONAL
Phase: PHASE2
Primary purpose: TREATMENT
Intervention type: DRUG, OTHER
Interventions: Eribulin, SDX-7320, Placebo
Lead sponsor: Memorial Sloan Kettering Cancer Center (OTHER)

Cached at: 2026-09-10 09:08:29

View on ClinicalTrials.gov

Brief summary

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report